A Phase 1/2 Open-label Study Investigating the Safety Tolerability and Efficacy of ASP7517 in subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Brief description of study

The purpose of the study is to evaluate the safety and tolerability of intravenous infusion of ASP7517 (human embryonic kidney cell transfected with encoding target antigen Wilms’ tumor protein 1). We also want to evaluate the anticancer activity of ASP7517. The study drug ASP7517 is investigational, which means that the study drug has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-01162
ClinicalTrials.gov Identifier: NCT04079296
Principal Investigator: Mohammad Maher Abdul Hay.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.